Late respiratory effects of sulfur mustard: how is the early symptoms severity involved?

Abstract

The association between severity of exposure to sulfur mustard (SM) and late respiratory complications is not clear. The aim of this study was to determine the presence of late pulmonary complications in patients with mild, moderate, and severe initial symptoms of sulfur mustard exposure. This was a retrospective cohort study on patients with mild, moderate, and severe initial symptoms of sulfur mustard exposure (during 1983–1988) in Baqyatallah University of medical sciences (2004–2005). The ‘mild’ group (n = 115) had no early symptom at the time of exposure. The ‘moderate’ group (n = 273) had early symptoms after exposure and were not hospitalized for that reason. The ‘severe’ group (n = 215) had early symptoms and had been hospitalized accordingly. Pulmonary function tests and high-resolution computed tomography of the chest were performed. The chi-square test was used for data analysis. The severe and moderate groups had a similar frequency of obstructive pattern (21%), whereas only one patient in the mild group showed this pattern. Air trapping did not significantly differ between groups. In the mild group, 74.8% (n = 86) showed significant air trapping, whereas it was 62.3% (n = 170) in moderate and 67.0% (n = 144) in severe groups (P = 0.057). Moderate and severe exposure to sulfur mustard causes an equal risk of late pulmonary complications, while mild exposure has lesser risk. Bronchiolitis obliterans is the main underlying respiratory consequence of sulfur mustard exposures and may relate to host factors rather than to severity of early symptoms.

Keywords

mustard gas late complications symptons severity respiratory

References

1 United Nations Security Council . : Report of the mission dispatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. S/19823. United Nations, New York, 1988.

2 Balali-Mood M Hefazi M . Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clini Pharmacol Toxicol 2006; 99: 273–282.

3 Khateri S Ghanei M Soroush M Haines D . Incidence of lung, eye and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 452: 1136–1143.

4 Balali M Hefazi M . The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 2005; 19: 297-315.

5 Sidell FR . Clinical notes on chemical casualty care. In: USAARMICD technical memorandum. U.S. Army Medical Research Institute of Chemical Defense. Aberdeen Providing Ground, Aberdeen, 1990; pp. 90–91.

6 Papirmeister B Feister AJ Robinson SI Ford RD . Medical defense against mustard gas: Toxic mechanisms and pharmacological implications. Boca Raton, Florida: CRC Press, 1991.

7 Sartin JS . Gulf war illnesses: cases and controversies. Mayo Clin Proc 2000; 75: 811–819.

9 Ghanei M Fathi H Mohammad M Aslani J Nematizadeh F . Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol 2004; 16: 491–495.

10.

10 McGuinness G Naidich DP . CT of airways disease and bronchiectasis. Radiol Clin North Am 2002; 40: 1–19.

11.

11 Muller NL Bergin CJ Ostrow DN . Role of computed tomography in the recognition of bronchiectasis. AJR Am J Roentgenol 1984; 143: 971–976.

12.

12 Hansell DM . Bronchiectasis. AJR Am J Roentgenol 1993; 160: 253–259.

13.

13 Stem EJ Swensen SJ Hartman TE Frank MS . CT mosaic pattern of lung attenuation: distinguishing different causes. AJR Am J Roentgenol 1995; 165: 813–816.

14.

14 Webb WR Stern EJ Kanth N Gamsu G . Dynamic pulmonary CT: findings in healthy adult men. Radiology 1993; 186: 111–124.

15.

15 American Thoracic Society . Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107–1136.

16.

16 Golshan M Nematbakhsh M Amra B Crapo RO . Spirometric reference values in a large Middle Eastern population. Eur Respir J 2003; 22: 529–534.

17.

17 Pauwels RA Buist AS Calverley PM Jenkins CR Hurd SS . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001 163: 1256–1276.

18.

18 McDuffie H Pahwa P Dosman JA . Respiratory health status of 3098 Canadian grain workers studied longitudinal. Am J Ind Med 1991; 20: 753–762.

19.

19 Emad A Rezaian GR . The diversity of effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: Analysis of 197 cases. Chest 1997; 112: 734–738.

20.

20 Hefazi M Attaran D Mahmoudi M Balali-Mood M . Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol 2005; 17: 587–592.

21.

21 Ghanei M Fathi H Mohammad MM Aslani J Nematizadeh F . Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol 2004; 16: 491–495.

22.

22 Bagheri MH Hosseini SK Mostafavi SH Alavi SA . High-resolution CT in chronic pulmonary changes after mustard gas exposure. Acta Radiol 2003; 44: 241–245.

23.

23 Dompeling E Jobsis Q Vandevijver NM Wesseling G Hendriks H . Chronic bronchiolitis in a 5-yr-old child after exposure to sulphur mustard gas. Eur Respir J 2004; 23: 343–346.

24.

24 Ghanei M Mokhtari M Mohammad MM Aslani J . Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol 2004; 52: 164–169.

25.

25 Beheshti J Mark EJ Akbari H Ghanei M . Mustard lung secrets: long term clinicopathological study following mustard Gas exposure. Pathol Res Pract 2006; 202: 739–744.

26.

26 Kraft M Mortenson RL Colby TV Newmann L Waldron JA King TE . Cryptogenic constrictive bronchiolitis. Am Rev Respir Dis 1993; 148: 1093–1101.

27.

27 Thomason JW Rice TW Milstone AP . Bronchiolitis obliterans in a survivor of a chemical weapons attack. JAMA 2003; 290: 598–599.

28.

28 Selman M . Pulmonary fibrosis: human and experimental disease. In: M Rojkind , (ed) Focus on connective tissue on health and diseasey. Boca Raton, Florida: CRC; 1989, pp. 123–188.

29.

29 Antonidas HN Bravo Avila R Galonopoulus T Neville J Maxwell M Selman M . Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055–1064.

30.

30 Blobe GC Schiemann WP Lodish HF . Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350–1358.

31.

31 Awad MR El-Gamel A Hasleton P Turner DM Sinnott PJ Hutchinson IV . Genotypic variation in the transforming growth factorbeta1 gene: association with TGF-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014–1020.

32.

32 Crouch E . Pathophysiology of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 1990; 259: L159–L184.

33.

33 Eickelberg O Köhler E Reichenberger F Bertschin S Woodtli T Erne P . Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-β1 and TGF-β3. Am J Physiol Lung Cell Mol Physiol 1999; 276: L814–L824.

34.

34 Khalil N O’Connor RN Unruh HW Warren PW Flanders KC Kemp A . Increased production and immunohistochemical localization of transforming growth factor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 155–162.

35.

35 El-Gamel A Sim E Hasleton P Hutchinson J Yonan N Egan J . Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828–837.

36.

36 Aghanouri R Ghanei M Aslani J Keivani-Amine H Rastegar F Karkhane A . Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287: 1160–1164.

37.

37 Kehe K Szinicz L . Medical aspects of sulphur mustard poisoning. Toxicology 2005; 214: 198–209.